Lisa J Caproni
Overview
Explore the profile of Lisa J Caproni including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
62
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Stirling D, de Miguel Ferrer M, Kim S, Wane M, Kysh D, Caproni L, et al.
Hum Vaccin Immunother
. 2025 Jan;
21(1):2430826.
PMID: 39829233
The COVID-19 pandemic highlighted the need for rapidly deployable, flexible vaccine platforms; particularly RNA which is now being explored for several other pathogens. DNA vaccines have potential advantages over RNA,...
2.
Pinyon J, von Jonquieres G, Mow S, Abed A, Lai K, Manoharan M, et al.
Adv Sci (Weinh)
. 2024 Nov;
12(3):e2406545.
PMID: 39601152
Viral vector and lipid nanoparticle based gene delivery have limitations around spatiotemporal control, transgene packaging size, and vector immune reactivity, compromising translation of nucleic acid (NA) therapeutics. In the emerging...
3.
Cunliffe R, Stirling D, Razzano I, Murugaiah V, Montomoli E, Kim S, et al.
Discov Immunol
. 2024 Apr;
3(1):kyad030.
PMID: 38567290
Influenza virus represents a challenge for traditional vaccine approaches due to its seasonal changes and potential for zoonotic transmission. Nucleic acid vaccines can overcome some of these challenges, especially through...
4.
Thornton C, Fielding S, Karbowniczek K, Roig-Merino A, Burrows A, FitzPatrick L, et al.
Mol Ther Methods Clin Dev
. 2021 Nov;
23:348-358.
PMID: 34729381
The application of induced pluripotent stem cells (iPSCs) in advanced therapies is increasing at pace, but concerns remain over their clinical safety profile. We report the first-ever application of doggybone...
5.
Karda R, Counsell J, Karbowniczek K, Caproni L, Tite J, Waddington S
Gene Ther
. 2019 Jan;
26(3-4):86-92.
PMID: 30643205
The manufacture of large quantities of high-quality DNA is a major bottleneck in the production of viral vectors for gene therapy. Touchlight Genetics has developed a proprietary abiological technology that...
6.
Allen A, Wang C, Caproni L, Sugiyarto G, Harden E, Douglas L, et al.
Cancer Immunol Immunother
. 2018 Jan;
67(4):627-638.
PMID: 29330557
Vaccination with DNA that encodes cancer antigens is a simple and convenient way to raise immunity against cancer and has already shown promise in the clinical setting. Conventional plasmid DNA...
7.
Scott V, Patel A, Villarreal D, Hensley S, Ragwan E, Yan J, et al.
Hum Vaccin Immunother
. 2015 Jun;
11(8):1972-82.
PMID: 26091432
Nucleic acid-based vaccines (NAVs) are a promising alternative to conventional influenza vaccines with the potential to increase influenza vaccine availability due to their simplicity in design and rapid speed of...
8.
Kinnear E, Caproni L, Tregoning J
PLoS One
. 2015 Jun;
10(6):e0130375.
PMID: 26091084
DNA vaccines can be manufactured cheaply, easily and rapidly and have performed well in pre-clinical animal studies. However, clinical trials have so far been disappointing, failing to evoke a strong...